Abstracts tagged "signal transduction and systemic lupus erythematosus (SLE)"

Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 2109 • 2018 ACR/ARHP Annual Meeting
Activation of T Follicular Helper Cells through Epigenetic Regulation By STAT1 and STAT4 in Lupus Patients
Shingo Nakayamada¹, Xiaoxue Ma¹, Satoshi Kubo¹, Yusuke Miyazaki¹, Kaoru Yamagata¹, Kazuhisa Nakano¹ and Yoshiya Tanaka², ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: During the T cell differentiation, signal transducer and activators of transcription (STAT) family transcription factors play pivotal roles in specifying T cell lineages. T…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 674 • 2012 ACR/ARHP Annual Meeting
Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling
Nan-Hua Chang¹, Timothy Li², Paul R. Fortin³, Dafna D. Gladman⁴, Carolina Landolt-Marticorena⁵, Jorge Sanchez-Guerrero⁶, Murray B. Urowitz⁷ and Joan E. Wither⁸, ¹Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸1E420/Div of Rheumatology, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Altered B cell signaling has been proposed to play an important role in susceptibility to SLE. In mice, genetic manipulations or polymorphisms that attenuate…
Abstract Number: 666 • 2012 ACR/ARHP Annual Meeting
Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via Degradation of an Adaptor Protein
Kristen Lee¹, Joanne H. Reed², Vineet Gupta³, Tejaskumar Patel², Jill P. Buyon⁴ and Robert M. Clancy², ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 33136, U.S.A., Miami, FL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus is characterized by continuous and cyclic stimulation of the innate immune system by endogenous nucleic acids. Immune complexes of Ro60, ssRNA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].